{"id":"mefenorex","rwe":[{"pmid":"22939380","year":"2012","title":"Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, \"spice\" and stimulants in oral fluid.","finding":"","journal":"Journal of chromatography. A","studyType":"Clinical Study"},{"pmid":"11897973","year":"2002","title":"Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.","finding":"","journal":"Therapeutic drug monitoring","studyType":"Clinical Study"},{"pmid":"10711406","year":"2000","title":"Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine.","finding":"","journal":"Drug metabolism reviews","studyType":"Clinical Study"},{"pmid":"9449560","year":"1997","title":"Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.","finding":"","journal":"Journal of chromatography. B, Biomedical sciences and applications","studyType":"Clinical Study"},{"pmid":"8911643","year":"1996","title":"Hair analysis for drugs of abuse. XIII. Effect of structural factors on incorporation of drugs into hair: the incorporation rates of amphetamine analogs.","finding":"","journal":"Archives of toxicology","studyType":"Clinical Study"}],"tags":[{"label":"mefenorex","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A08AA09","category":"atc"},{"label":"Active","category":"status"},{"label":"Obesity","category":"indication"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MEFENOREX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:38:06.830655+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:38:21.092706+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:38:12.189114+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEFENOREX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:38:12.948503+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2110962/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:38:13.747107+00:00"}},"allNames":"rondimen","offLabel":[],"synonyms":["chloropropylamphetamine","mefenorex","rondimen","mefenorex hydrochloride","mefenorex HCl"],"timeline":[],"aiSummary":"Mefenorex (Rondimen) is a marketed obesity treatment that operates by blocking the reabsorption of neurotransmitters involved in appetite and metabolism regulation. Its key competitive advantage lies in its unique mechanism of action and the patent protection extending to 2028, which may limit generic competition. However, the primary risk is the presence of multiple off-patent competitors such as phentermine and diethylpropion, which could erode market share.","approvals":[],"brandName":"Rondimen","ecosystem":[{"indication":"Obesity","otherDrugs":[{"name":"amfetamine","slug":"amfetamine","company":"Ucb Inc"},{"name":"benzphetamine","slug":"benzphetamine","company":"Pharmacia And Upjohn"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"chlorphentermine","slug":"chlorphentermine","company":"Parke Davis"}],"globalPrevalence":890000000}],"mechanism":{"modality":"Small Molecule","drugClass":"mefenorex","explanation":"","oneSentence":"","technicalDetail":"Mefenorex is a norepinephrine reuptake inhibitor (NRI), which increases the concentration of norepinephrine in the synaptic cleft, enhancing its effects on the sympathetic nervous system and increasing lipolysis and thermogenesis."},"commercial":{"revenueYear":2025,"annualRevenue":172,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1664","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEFENOREX","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:33:09.630040","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:38:21.092779+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"phentermine","drugSlug":"phentermine","fdaApproval":"1959-05-04","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenfluramine","drugSlug":"fenfluramine","fdaApproval":"2020-06-25","patentExpiry":"Nov 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diethylpropion","drugSlug":"diethylpropion","fdaApproval":"1959-08-06","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mazindol","drugSlug":"mazindol","fdaApproval":"1973-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sibutramine","drugSlug":"sibutramine","fdaApproval":"1997-11-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lorcaserin","drugSlug":"lorcaserin","fdaApproval":"2012-06-27","relationship":"same-class"},{"drugName":"setmelanotide","drugSlug":"setmelanotide","fdaApproval":"2020-11-25","patentExpiry":"Oct 13, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"mefenorex","indications":{"approved":[{"name":"Obesity","source":"DrugCentral","snomedId":414916001,"regulator":"FDA","usPrevalence":100000000,"globalPrevalence":890000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phentermine","brandName":"phentermine","genericName":"phentermine","approvalYear":"1959","relationship":"same-class"},{"drugId":"fenfluramine","brandName":"fenfluramine","genericName":"fenfluramine","approvalYear":"2020","relationship":"same-class"},{"drugId":"diethylpropion","brandName":"diethylpropion","genericName":"diethylpropion","approvalYear":"1959","relationship":"same-class"},{"drugId":"mazindol","brandName":"mazindol","genericName":"mazindol","approvalYear":"1973","relationship":"same-class"},{"drugId":"sibutramine","brandName":"sibutramine","genericName":"sibutramine","approvalYear":"1997","relationship":"same-class"},{"drugId":"lorcaserin","brandName":"lorcaserin","genericName":"lorcaserin","approvalYear":"2012","relationship":"same-class"},{"drugId":"setmelanotide","brandName":"setmelanotide","genericName":"setmelanotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-class"},{"drugId":"ephedrine","brandName":"ephedrine","genericName":"ephedrine","approvalYear":"","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005309","UNII":"K98M4N387W","CHEBI":"CHEBI:134883","INN_ID":"2494","RXNORM":"236179","UMLSCUI":"C0065870","chemblId":"CHEMBL2110962","ChEMBL_ID":"CHEMBL2110962","KEGG_DRUG":"D04893","DRUGBANK_ID":"DB13852","PUBCHEM_CID":"21777","SNOMEDCT_US":"96245004","SECONDARY_CAS_RN":"5586-87-8","MESH_SUPPLEMENTAL_RECORD_UI":"C000450"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":18,"therapeuticAreas":["Metabolic"],"_revenueScrapedAt":"2026-03-31 14:09:35.487336+00","atcClassification":{"source":"DrugCentral","atcCode":"A08AA09","allCodes":["A08AA09"]},"biosimilarFilings":[],"recentPublications":[{"date":"2012 Oct 5","pmid":"22939380","title":"Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, \"spice\" and stimulants in oral fluid.","journal":"Journal of chromatography. A"},{"date":"2002 Apr","pmid":"11897973","title":"Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.","journal":"Therapeutic drug monitoring"},{"date":"2000 Feb","pmid":"10711406","title":"Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine.","journal":"Drug metabolism reviews"},{"date":"1997 Nov 21","pmid":"9449560","title":"Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.","journal":"Journal of chromatography. B, Biomedical sciences and applications"},{"date":"1996","pmid":"8911643","title":"Hair analysis for drugs of abuse. XIII. Effect of structural factors on incorporation of drugs into hair: the incorporation rates of amphetamine analogs.","journal":"Archives of toxicology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:38:21.092779+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}